Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genovis AB's revenue for the
three
months ended in Jun. 2026 was kr34.3 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was kr135.6 Mil.
Genovis AB's Revenue per Share for the
three
months ended in Jun. 2026 was kr0.52.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was kr2.05.
During the past 12 months, the average Revenue per Share Growth Rate of Genovis AB was 10.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 7.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 15.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 22.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Genovis AB's highest 3-Year average Revenue per Share Growth Rate was 37.10% per year. The lowest was -2.30% per year. And the median was 10.20% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Genovis AB Revenue Related Terms
Genovis AB Revenue Historical Data
* Premium members only.
The historical data trend for Genovis AB's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genovis AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovis AB Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovis AB's Revenue distribution charts can be found below:
* The bar in red indicates where Genovis AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr135.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovis AB (OSTO:GENO) has a Revenue of kr135.6 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Genovis AB and its competitors.
Is Genovis AB's Revenue too high?
Genovis AB's current Revenue is kr135.6 Mil. Overall, Genovis AB has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's Revenue compare to VRTX and REGN?
Genovis AB's Revenue of kr135.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Genovis AB and its competitors. Genovis AB's current Revenue is kr135.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Based on GuruFocus' analysis, Genovis AB (OSTO:GENO) is currently considered Modestly Undervalued. The stock's GF Value™ is kr26.74, compared to a current price of kr20.70 — trading 22.6% below its estimated fair value. The current Revenue is kr135.6 Mil. Genovis AB's overall GF Score™ is 96/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Genovis AB (OSTO:GENO), the current Revenue is kr135.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovis AB (OSTO:GENO) Overvalued in 2026?
Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued.
The current stock price of kr20.70 is trading 22.6% below its estimated GF Value™ of kr26.74.
GuruFocus considers Genovis AB to be Modestly Undervalued.
Key valuation signals for OSTO:GENO:
Revenue: kr135.6 Mil
GF Value™: kr26.74 vs. price of kr20.70 (22.6% below fair value)
No single metric tells the full story. See the OSTO:GENO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
96GF Score
Get the complete analysis for OSTO:GENO
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:GENO has been successfully added to your 
